The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 1.40
High: 1.40
Low: 1.40
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Installation at Barrow Neurological Institute

11 Dec 2018 07:00

RNS Number : 9988J
IQ-AI Limited
11 December 2018
 

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics® installation at Barrow Neurological Institute

Imaging Biometrics®, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that Barrow Neurological Institute: Dignity Health, St. Joseph's Hospital and Medical Center ("BNI") has installed a new IB Rad Tech software platform to help assess treatment response for patients with brain tumors. BNI has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. IB Rad Tech was chosen for its ability to efficiently generate quantitative maps of enhancing regions of tumor (Delta T1) and fractional tumor burden ("FTB"). IB's perfusion-derived FTB maps have been shown to aid clinicians in distinguishing tumor from non-tumor tissue.

IB Rad Tech offers customised workflows that automate the generation of sophisticated maps, outputs quality assurance indices, and can allow manual acknowledgement and intervention during intermediate processing steps. For example, one workflow used in generating quantitative Delta T1 and FTB maps relies on an exclusive machine-learned calibration technology termed "standardisation", which works for all platforms and field strengths. This step has proven superior to conventional normalisation techniques as it eliminates the need for the manual placement of regions of interest (ROIs) by radiology staff or physicians thereby reducing error and improving workflow efficiencies.

David Smith, CEO of IB, said, "Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumor patients. Removing the variability of the manually-placed ROI is a more repeatable and faster method to do inter- and intra-study comparisons for multi-center clinical trials as well."

"Without IB Rad Tech, we would not be able to process the high volume of studies we see at our site," said Dr. John Karis, MD, Director of MRI and brain imaging for the Department of Neuroradiology at Barrow Neurological Institute, Dignity Health St. Joseph's Hospital and Medical Center. "Our MR Technologists are now able to quickly and consistently generate IB's advanced maps, and the clinicians trust the science on which Delta T1 and FTBs are based", added Josef Debbins, PhD, Staff Scientist, Keller Center for Imaging Innovation at Barrow.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Fungai Ndoro

Tel: 020 7220 9797

 

Barrow Neurological Institute / Dignity Health St. Joseph's Hospital and Medical Center has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. Since 1962, Barrow has grown into one of the premiere destinations in the world for neurology and neurosurgery. Experienced, highly skilled, and comprehensive teams of neurological specialists provide a complete spectrum of care-from diagnosis through outpatient neurorehabilitation-under one roof. Barrow Neurological Institute: Discover. Educate. Heal.

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides -visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

IQ-AI Limited (Ticker:IQAI) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.iq-ai.ltd).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRGGGUAPUPRGWU
Date   Source Headline
1st Oct 201911:00 amRNSPrice Monitoring Extension
1st Oct 20199:05 amRNSSecond Price Monitoring Extn
1st Oct 20199:00 amRNSPrice Monitoring Extension
1st Oct 20197:01 amRNSStoneChecker USA Market Introduction
1st Oct 20197:00 amRNSIssue of Equity
30th Sep 201911:05 amRNSSecond Price Monitoring Extn
30th Sep 201911:00 amRNSPrice Monitoring Extension
27th Sep 20197:00 amRNSFDA Clearance to Market for StoneChecker Software
16th Sep 20199:34 amRNSReplacement - Half Yearly Report to 30 June 2019
16th Sep 20197:00 amRNSHalf-year Report
4th Sep 20197:00 amRNSGrant Award
6th Aug 20197:00 amRNSCompletion of Placing and Conversion of Loan Notes
5th Aug 20192:05 pmRNSSecond Price Monitoring Extn
5th Aug 20192:00 pmRNSPrice Monitoring Extension
9th Jul 20197:00 amRNSUpdate on Gadolinium Free Imaging Project
26th Jun 20197:00 amRNSPlacing
24th Jun 20192:52 pmRNSHolding(s) in Company
20th Jun 20194:40 pmRNSSecond Price Monitoring Extn
20th Jun 20194:35 pmRNSPrice Monitoring Extension
12th Jun 20197:00 amRNSBusiness Development Agreement with CorTechs Labs
6th Jun 201911:49 amRNSResult of AGM
29th May 201911:51 amRNSIssue of Convertible Loan Notes - Correction
29th May 20198:22 amRNSIssue of Convertible Loan Notes
17th May 201912:00 pmRNSExtension of Loan Notes Redemption Date
9th May 20191:30 pmRNSNotice of AGM
9th May 201912:13 pmRNSHolding(s) in Company
30th Apr 201912:00 pmRNSPublication of Annual Report
2nd Apr 20197:00 amRNSImaging Biometrics Update
11th Mar 20197:00 amRNSIssue of Convertible Loan Notes
8th Feb 201910:29 amRNSBusiness Update
2nd Jan 201912:20 pmRNSHolding(s) in Company
13th Dec 20189:00 amRNSPrice Monitoring Extension
13th Dec 20187:00 amRNSStoneChecker 510k Update
11th Dec 20187:00 amRNSInstallation at Barrow Neurological Institute
28th Nov 20187:00 amRNSImaging Biometrics® Update
16th Nov 20187:00 amRNSFirst Commercial Sale of StoneChecker Software
22nd Oct 20187:00 amRNSIQ-AI files patent for Contrast-Free Imaging
4th Oct 20182:58 pmRNSResult of EGM and Change of Name
27th Sep 20187:00 amRNSIB announce agreement to develop a diagnostic tool
18th Sep 20187:00 amRNSProposed name change and notice of EGM
11th Sep 20189:00 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Sep 20187:00 amRNSHalf-year Report
6th Aug 20182:51 pmRNSHolding(s) in Company
6th Aug 20187:00 amRNSAppointment of CEO to the Operating Subsidiaries
1st Aug 20184:28 pmRNSPublication of a Prospectus
31st Jul 20183:54 pmRNSResult of AGM and GM
18th Jul 20181:24 pmRNSNon Regulatory - Vox Markets Podcast
18th Jul 20188:57 amRNSHolding(s) in Company
17th Jul 20187:00 amRNSECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IB

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.